MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer

BACKGROUND: Metastatic castration resistant prostate cancer (mCRPC) is incurable and progression after drugs that target the androgen receptor-signaling axis is inevitable. Thus, there is an urgent need to develop more effective treatments beyond hormonal manipulation. We sought to identify activate...

Descripción completa

Detalles Bibliográficos
Autores principales: Nickols, Nicholas G., Nazarian, Ramin, Zhao, Shuang G., Tan, Victor, Uzunangelov, Vladislav, Xia, Zheng, Baertsch, Robert, Neeman, Elad, Gao, Allen C., Thomas, George V., Howard, Lauren, De Hoedt, Amanda M., Stuart, Josh, Goldstein, Theodore, Chi, Kim, Gleave, Martin E., Graff, Julie N., Beer, Tomasz M., Drake, Justin M., Evans, Christopher P., Aggarwal, Rahul, Foye, Adam, Feng, Felix Y., Small, Eric J., Aronson, William J., Freedland, Stephen J., Witte, Owen N., Huang, Jiaoti, Alumkal, Joshi J., Reiter, Robert E., Rettig, Matthew B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853839/
https://www.ncbi.nlm.nih.gov/pubmed/30804427
http://dx.doi.org/10.1038/s41391-019-0134-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853839/
https://www.ncbi.nlm.nih.gov/pubmed/30804427
http://dx.doi.org/10.1038/s41391-019-0134-5

Ejemplares similares